Experience (1 year) of G-CSF biosimilars in PBSCT for lymphoma and myeloma patients

摘要

The costs of medical care are always increasing. To limit them, several pharmaceutical laboratories have developed substitutes of effective, but costly, products. They have produced biosimilars of G-CSF-like filgrastim—Neupogen from Amgen pharmaceutical (Thousand Oaks, CA, USA). The methods of synthesis are quite different from the synthesis of the original product because they utilise bacterial support to yield new bioproducts with lower costs, but that induces modifications of the molecules like glycosylation and phosphorylation. But, final products already seem to be as effective as the classical version of G-CSF. Despite the limited number of prospective studies in the field of haematology, these biosimilars were awarded the same authorisations of use as those of the original product. There are few data available on the use of biosimilars of filgrastim in PBSCT. Because of the potentially decreased costs, biosimilars of G-CSF have become available in our hospital. Over the course of a year, we have used these products for patients with lymphoma and myeloma who underwent PBSCT. We initiated a retrospective study comparing the efficacy on BM recovery with the use of biosimilars of G-CSF vs a historical cohort of patients.